A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.
Launched by HOFFMANN-LA ROCHE · Jul 17, 2007
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, 18-75 years of age;
- • rheumatoid arthritis for \>=3 months and \<=10 years;
- • inadequate response to methotrexate (12.5-25mg/week) for \>=3 months;
- • evidence of erosive disease and/or clinical synovitis in a signal joint.
- Exclusion Criteria:
- • autoimmune rheumatic diseases other than RA;
- • surgical operations on bones/joints in 12 weeks prior to baseline visit;
- • concomitant treatment with biologic agents;
- • previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Genova, Liguria, Italy
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials